| |
|
Product Name:
|
Enterotoxigenic Escherichia coli Double Mutant Heat-Labile Toxoid (dmLT), Adjuvant-Active, Recombinant from Escherichia coli
|
|
Ownership statement:
|
This reagent is the tangible property of the U.S. Government.
|
|
Manufacturer:
|
Jacob P. Bitoun, Ph.D., Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA
|
|
Material Provided:
|
Each vial of NR-51682 contains approximately 2 mg of purified recombinant dmLT adjuvant, which was lyophilized from TEAN (Tris, EDTA, sodium azide and sodium chloride) buffer.1
Note: Resuspend slowly with 2.0 mL of HyClone water and gently mix by hand to dissolve. The solution may appear slightly turbid.
|
|
Packing/Storage:
|
NR-51682 was packaged aseptically in glass vials, lyophilized and sealed under vacuum.1 The product is provided at room temperature and should be stored at 2°C to 8°C immediately upon arrival. Freeze-thaw cycles should be avoided.
|
|
Functional Activity:
|
NR-51682 is functional in SDS-PAGE, cAMP assays in human colorectal carcinoma (T84) cells, western blot and oral adjuvanticity (ELISA) assays.1,2 The novel dmLT adjuvant promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.1,2
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.
|
|
Patents or other restrictions:
|
NR-51682 is claimed in U.S. Patent Numbers 6,019,982 and 6,033,673, and the continuations, continuations-in-part, re-issues and foreign counterparts thereof.1
|
References:
|
1. Bitoun, J. P., Personal Communication.
2. Norton, E. B., et al. “Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant.” Clin. Vaccine Immunol. 18 (2011): 546-551. PubMed: 21288994.
3. Beachey, E. H. “Bacterial Adherence: Adhesin-Receptor Interactions Mediating the Attachment of Bacteria to Mucosal Surface.” J. Infect. Dis. 143 (1981): 325-345. PubMed: 7014727.
4. Yamamoto, T. and T. Yokota. “Plasmids of Enterotoxigenic Escherichia coli H10407: Evidence for Two Heat-Stable Enterotoxin Genes and a Conjugal Transfer System.” J. Bacteriol. 153 (1983): 1352-1360. PubMed: 6298182.
5. Sixma, T. K., et al. “Lactose Binding to Heat-Labile Enterotoxin Revealed by X-Ray Crystallography.” Nature 355 (1992): 561-564. PubMed: 1741035.
6. Toprani, V. M., et al. “Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant.” J. Pharm. Sci. 106 (2017): 3474-3485. PubMed: 28780391.
|
|
Citation:
|
Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Enterotoxigenic Escherichia coli Double Mutant Heat-Labile Toxoid (dmLT), Adjuvant-Active, Recombinant from Escherichia coli, NR-51682.”
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|